This is a listing of Requests for Applications (RFA), Program Announcements (PA), and Notices specific to the group's key programs.
Standard submission dates apply for all listings, unless otherwise noted.
Guidance For Investigators Planning to Submit a Program Project Grant (P01)
Notice: Internet links not permitted in NIH Grant Applications
Information about the funding opportunity announcements that align with the efforts of the Cancer MoonshotSM can be found here: https://www.cancer.gov/research/key-initiatives/moonshot-cancer-initiative/funding.
| Title | Announcement # | Expiration Date | Research Focus |
|---|---|---|---|
| Academic-Industrial Partnerships (AIP) to Translate and Validate In Vivo Imaging Systems | PAR-20-155 (R01 Clinical Trial Optional) | 09/08/2022 |
|
| Administrative Supplement for Research on Dietary Supplements (Admin Supp-Clinical Trial Not Allowed) | PA-20-227 | 04/16/2023 |
|
| Advanced Development and Validation of Emerging Biospecimen Science Technologies for Basic and Clinical Cancer Research | RFA-CA-21-006 (R33 Clinical Trial Not Allowed) | 09/30/2021 |
|
| Advanced Development and Validation of Emerging Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research | RFA-CA-21-004 (R33 Clinical Trial Not Allowed) | 09/29/2021 |
|
| Advanced Development of Informatics Technologies for Cancer Research and Management | RFA-CA-21-015 (U24 Clinical Trial Optional) | 11/18/2021 |
|
| Assay Validation of High Quality Markers for Clinical Studies in Cancer | PAR-20-314 (UH3 Clinical Trials Not Allowed) | 10/11/2023 |
|
| Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH2/UH3 Clinical Trial Not Allowed) | PAR-20-313 | 10/11/2023 |
|
| Basic and Translational Research on Adducts in Cancer Risk Identification and Prevention | PAR-19-252 (R21 Clinical Trial Optional) | 11/09/2021 |
|
| Basic and Translational Research on Adducts in Cancer Risk Identification and Prevention | PAR-19-251 (R01 Clinical Trial Optional) | 11/09/2021 |
|
| Basic Research in Cancer Health Disparities | PAR-21-322 (R01 Clinical Trial Not Allowed) | 09/08/2024 |
|
| Basic Research in Cancer Health Disparities | PAR-21-324 (R03 Clinical Trial Not Allowed) | 09/08/2024 |
|
| Basic Research in Cancer Health Disparities | PAR-21-323 (R21 Clinical Trial Not Allowed) | 09/08/2024 |
|
| Biology of Bladder Cancer | PAR-19-183 (R01 Clinical Trial Optional) | 05/08/2022 |
|
| Biology of Bladder Cancer | PAR-19-184 (R21 Clinical Trial Optional) | 05/08/2022 |
|
| Cancer Prevention and Control Clinical Trials Grant Program | PAR-21-035 (R01 Clinical Trial Required) | 01/08/2024 |
|
| Cancer Prevention-Interception Targeted Agent Discovery Program (CAP-IT) Centers | RFA-CA-21-038 (U54 Clinical Trial Not Allowed) | 10/08/2021 |
|
| Cancer Prevention-Interception Targeted Agent Discovery Program (CAP-IT) Data and Resource Coordination Center (CAP-IT DRCC) | RFA-CA-21-039 (U24 Clinical Trial Not Allowed) | 10/08/2021 |
|
| Cancer Tissue Engineering Collaborative: Enabling Biomimetic Tissue-Engineered Technologies for Cancer Research | PAR-19-113 (R01 Clinical Trial Optional) | 01/08/2022 |
|
| Clinical Characterization of Cancer Therapy-induced Adverse Sequelae and Mechanism-based Interventional Strategies | PAR-19-325 (R01 Clinical Trial Optional) | 02/12/2022 |
|
| Co-infection and Cancer | PAR-20-062 (R01 Clinical Trial Not Allowed) | 01/08/2023 |
|
| Development of Innovative Informatics Methods and Algorithms for Cancer Research and Management | RFA-CA-21-013 (R21 Clinical Trial Optional) | 11/18/2021 |
|
| Early-Stage Development of Informatics Technologies for Cancer Research and Management | RFA-CA-21-014 (U01 Clinical Trial Optional) | 11/18/2021 |
|
| Imaging, Biomarkers and Digital Pathomics for the Early Detection of Premetastatic Aggressive Cancer | PAR-19-264 (R01 Clinical Trial Optional) | 12/11/2021 |
|
| Improving Outcomes in Cancer Treatment-Related Cardiotoxicity | PA-19-111 (R21 Clinical Trial Optional) | 01/08/2022 |
|
| Improving Outcomes in Cancer Treatment-Related Cardiotoxicity | PA-19-112 (R01 Clinical Trial Optional) | 01/08/2022 |
|
| Innovative Biospecimen Science Technologies for Basic and Clinical Cancer Research | RFA-CA-21-005 (R21 Clinical Trial Not Allowed) | 09/30/2021 |
|
| Innovative Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research | RFA-CA-21-003 (R21 Clinical Trial Not Allowed) | 09/30/2021 |
|
| Mechanisms of Disparities in Chronic Liver Diseases and Cancer (R01- Clinical Trial Not Allowed) | PAR-20-088 | 04/02/2022 |
|
| Mechanisms of Disparities in Chronic Liver Diseases and Cancer (R21- Clinical Trial Not Allowed) | PAR-20-081 | 04/02/2022 |
|
| Mechanisms that Impact Cancer Risk after Bariatric Surgery | PAR-21-332 (R21 Clinical Trial Not Allowed) | 09/08/2024 |
|
| Mechanisms that Impact Cancer Risk after Bariatric Surgery | PAR-21-331 (R01 Clinical Trial Optional) | 09/08/2024 |
|
| Mechanisms Underlying the Contribution of Sleep Disturbances to Pain | PA-19-200 (R01 Clinical Trial Optional) | 05/08/2022 |
|
| Mechanisms Underlying the Contribution of Sleep Disturbances to Pain | PA-19-201 (R21 Clinical Trial Optional) | 05/08/2022 |
|
| Modulating Intestinal Microbiota to Enhance Protective Immune Responses against Cancer | PAR-19-198 (R01 Clinical Trial Not Allowed) | 11/09/2021 |
|
| Modulating Intestinal Microbiota to Enhance Protective Immune Responses against Cancer | PAR-19-199 (R21 Clinical Trial Not Allowed) | 11/09/2021 |
|
| Music and Health: Understanding And Developing Music Medicine | PAR-21-100 (R01 Clinical Trial Optional) | 02/06/2023 |
|
| Music and Health: Understanding And Developing Music Medicine | PAR-21-099 (R21 Clinical Trial Optional) | 02/17/2023 |
|
| NCI Clinical and Translational Exploratory/Developmental Studies | PAR-20-292 (R21 Clinical Trial Optional) | 07/21/2022 |
|
| Notice of Correction to Application Types Allowed for PAR-20-053, Program to Assess the Rigor and Reproducibility of Extracellular Vesicle-Derived Analytes for Cancer Detection | NOT-CA-20-067 (R01 Clinical Trial Not Allowed) | 01/08/2023 |
|
| Notice of Intent to Publish a Funding Opportunity Announcement for Clinical Sites for HIV/Cervical Cancer Prevention 'CASCADE' Clinical Trials Network | NOT-CA-21-114 (UG1 Clinical Trial Required) | 08/01/2022 |
|
| Notice of Intent to Publish a Funding Opportunity Announcement for Coordinating Center for HIV/Cervical Cancer Prevention 'CASCADE' Clinical Trials Network | NOT-CA-21-112 (U24 Clinical Trial Required) | 08/01/2022 |
|
| Notice of Intent to Publish a Funding Opportunity Announcement for Mechanisms that Impact Cancer Risk after Bariatric Surgery | NOT-CA-21-091 (R21 Clinical Trial Not Allowed) | 11/01/2021 |
|
| Notice of Intent to Publish a Funding Opportunity Announcement for Mechanisms that Impact Cancer Risk after Bariatric Surgery | NOT-CA-21-090 (R01 Clinical Trial Optional) | 11/01/2021 |
|
| Notice of Intent to Publish a Funding Opportunity Announcement for Research Bases for HIV/Cervical Cancer Prevention 'CASCADE' Clinical Trials Network | NOT-CA-21-113 (UG1 Clinical Trial Required) | 08/01/2022 |
|
| Notice of Special Interest: Advancing the Science of Geriatric Palliative Care | NOT-AG-20-041 | 09/08/2023 |
|
| Notice of Special Interest: Development of Swallowable Smart Pills or Devices for Precision Nutrition, Microbiome and Digestive Disease Applications | NOT-DK-20-001 | 01/08/2023 |
|
| Notice of Special Interest: National Cancer Institute Administrative Supplement Opportunity for Strategies to Optimize Recruitment and Retention of Cancer Prevention and Symptom Management Clinical Trial Participants | NOT-CA-21-070 | 05/16/2023 |
|
| Notice of Special Interest (NOSI): Advancing Head and Neck Cancer Early Detection Research (AHEAD) | NOT-CA-20-031 | 01/08/2022 |
|
| Notice of Special Interest (NOSI): Biology of Lung and Head and Neck Preneoplasia | NOT-CA-21-057 | 05/08/2023 |
|
| Notice of Special Interest (NOSI): Leveraging Real-World Imaging Data for Artificial Intelligence-based Modeling and Early Detection of Abdominal Cancers | NOT-CA-21-028 | 01/08/2024 |
|
| Notice of Special Interest (NOSI): Single-Cell Proteomics for Interrogating Premalignant and Early Malignant Lesions | NOT-CA-20-044 | 05/08/2023 |
|
| Notice of Special Interest: Small Business Development of Wearable Smart Devices for Continuous Monitoring of Circulating Nutrients, Metabolites and Hormones | NOT-DK-20-002 | 01/08/2023 |
|
| Pancreatic Cancer Detection Consortium: Management and Data Coordination Unit | PAR-21-335 (U24 Clinical Trial Not Allowed) | 06/12/2024 |
|
| Pancreatic Cancer Detection Consortium: Research Units | PAR-21-334 (U01 Clinical Trial Optional) | 06/12/2024 |
|
| Program to Assess the Rigor and Reproducibility of Extracellular Vesicle-Derived Analytes for Cancer Detection | PAR-20-053 (R01 Clinical Trial Not Allowed) | 01/08/2023 |
|
| Promoting Research on Music and Health: Phased Innovation Award for Music Interventions (R61/R33 Clinical Trial Optional) | PAR-20-266 | 06/20/2023 |
|
| Revision Applications for Validation of Biomarker Assays Developed Through NIH-Supported Research Grants | PAR-20-074 (R01 Clinical Trial Not Allowed) | 10/29/2022 |
|
| Revision Applications to Support the Application of Informatics Technology for Cancer Research | RFA-CA-21-017 (R01 Clinical Trials Optional) | 11/18/2021 |
|
| Revision Applications to Support the Application of Informatics Technology for Cancer Research | RFA-CA-21-019 (U24 Clinical Trial Optional) | 11/19/2021 |
|
| Revision Applications to Support the Application of Informatics Technology for Cancer Research | RFA-CA-21-018 (U01 Clinical Trials Optional) | 11/18/2021 |
|
| Secondary Analysis and Integration of Existing Data to Elucidate the Genetic Architecture of Cancer Risk and Related Outcomes | PAR-20-276 (R01 Clinical Trial Not Allowed) | 09/08/2022 |
|
| Secondary Analysis and Integration of Existing Data to Elucidate the Genetic Architecture of Cancer Risk and Related Outcomes | PAR-20-277 (R21 Clinical Trials Not Allowed) | 09/08/2022 |
|
| Stephen I. Katz Early Stage Investigator Research Project Grant | PAR-21-039 (R01 Basic Experimental Studies with Humans Required) | 12/29/2023 |
|
| Stephen I. Katz Early Stage Investigator Research Project Grant | PAR-21-038 (R01 Clinical Trial Not Allowed) | 12/29/2023 |
|
| Sustained Support for Informatics Technologies for Cancer Research and Management | RFA-CA-21-016 (U24 Clinical Trial Optional) | 11/18/2021 |
|
| Translational and Basic Science Research in Early Lesions (TBEL) | RFA-CA-21-054 (U54 Clinical Trial Not Allowed) | 11/03/2021 |
|
| Translational and Basic Science Research in Early Lesions (TBEL) Coordinating and Data Management Center | RFA-CA-21-055 (U24 Clinical Trial Not Allowed) | 11/03/2021 |
|
| Utilizing the PLCO Biospecimens Resource to Bridge Gaps in Cancer Etiology and Early Detection Research | PAR-21-330 (U01 Clinical Trial Not Allowed) | 10/12/2024 |
|
| Validation Studies of Analytical Methods for Dietary Supplement Constituents (Admin Supp - Clinical Trial Not Allowed) | PA-20-252 | 04/16/2022 |
|